WARSAW, Ind., Oct. 27, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the acquisition of RespondWell®, an award-winning telerehabilitation technology designed to provide personalized, clinician-supervised post-surgical physical therapy in the comfort of a patient's home. The acquisition strengthens the Company's recently announced Zimmer Biomet Signature Solutions commercial offering by integrating a comprehensive, at-home telerehabilitation capability designed to enhance patient compliance with physical therapy and improve the quality of recovery.
"The new value-based reimbursement environment compels hospitals and providers to assume responsibility for patient outcomes well after discharge and through the critical rehabilitation period," said David Nolan, Group President, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Office Based Technologies. "Integrating an innovative and comprehensive telerehabilitation program into our Zimmer Biomet Signature Solutions offering addresses the emerging need for healthcare providers to oversee and optimize post-surgical recovery outcomes in order to maximize value across the entire episode of care."
"I believe RespondWell's innovative telerehabilitation platform will help our clinical care team enhance the quality and outcomes of post-op patient care by providing an interactive and motivating physical therapy experience that encourages patient engagement and compliance to physical therapy in a convenient environment, the patient's home," said Ronald A. Navarro, M.D., Regional Coordinating Chief of Orthopedic Surgery, Kaiser Permanente.
Zimmer Biomet Signature Solutions is a strategically-curated suite of technologies and services designed to help hospitals and providers streamline delivery of care and succeed in today's value-based reimbursement environment. The Zimmer Biomet Signature Solutions remote rehabilitation platform, known as [email protected], features a personalized rehabilitation plan designed by a patient's clinical care team, video-gaming-style exercise system with on-screen digital instructors to coach and encourage patients, and built-in reward features earned through increased patient participation and consistency. The system also allows the patient's clinical care team to remotely monitor patient progress and activity and digitally communicate with the patient, potentially reducing the costs associated with follow-up visits and clinic-based rehabilitation programs. Zimmer Biomet is currently launching research partnerships for the Zimmer Biomet Signature Solutions suite at selected academic research institutions in the U.S., with a broader commercial release scheduled for 2017.
"Telerehabilitation represents the future of optimal and efficient post-surgical patient care, and we are excited to integrate our remote rehabilitation platform into the Zimmer Biomet Signature Solutions suite," said Ted Spooner, Co-founder and CEO of RespondWell.
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see our periodic reports filed with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Accordingly, such forward-looking statements speak only as of the date made. Readers of this news release are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
SOURCE Zimmer Biomet Holdings, Inc.